CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed

NCT05162976 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Classic Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma

Interventions

BIOLOGICAL: Nivolumab
DRUG: Oral Azacitidine

Sponsor

City of Hope Medical Center

Collaborators

[object Object]